
|Videos|November 14, 2020
AAO 2020: Study confirms Phase III results for uveitis treatment
Author(s)OT Staff Reports
Glenn J. Jaffe, MD, presents a summary of the results of a confirmatory study on a previous Phase III trial that examined sustained drug delivery for the treatment of uveitis, as well as data on the 36-month results in the second, confirmatory phase 3 study of YUTIQ.
Advertisement
Glenn J. Jaffe, MD, presents a summary of the results of a confirmatory study on a previous Phase III trial that examined sustained drug delivery for the treatment of uveitis, as well as data on the 36-month results in the second, confirmatory phase 3 study of YUTIQ.
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
FDA expands faricimab label to include treatment of macular edema secondary to retinal vein occlusion beyond 6 months
2
Tattoo-associated uveitis: An emerging eye health challenge
3
Ocugen completes dosing early in phase 2/3 GARDian3 trial for Stargardt disease
4


























